Company Description
Tempus AI, Inc operates as a healthcare technology company.
It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties.
The company also offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies.
In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data.
The company has a collaboration with united therapeutics to study use of AI to detect patients at risk for pulmonary hypertension.
The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc in January 2023.
Tempus AI, Inc was incorporated in 2015 and is headquartered in Chicago, Illinois.
| Country | United States |
| Founded | 2015 |
| IPO Date | Jun 14, 2024 |
| Industry | Health Information Services |
| Sector | Healthcare |
| Employees | 1,952 |
| CEO | Eric Lefkofsky |
Contact Details
Address: 600 West Chicago Avenue, Suite 510 Chicago, Illinois 60654 United States | |
| Phone | 800 976 5448 |
| Website | tempus.com |
Stock Details
| Ticker Symbol | TEM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $37.00 |
| CIK Code | 0001717115 |
| CUSIP Number | 71535D106 |
| ISIN Number | US88023B1035 |
| Employer ID | 47-4903308 |
| SIC Code | 7370 |
Key Executives
| Name | Position |
|---|---|
| Eric P. Lefkofsky | Co-Founder, Chief Executive Officer, President and Chairman |
| James Rogers | Chief Financial Officer |
| Ryan Fukushima | Chief Operating Officer |
| Shane Colley | Chief Technology Officer |
| Dr. Kate A. Sasser Ph.D. | Chief Scientific Officer |
| Erik Phelps | Executive Vice President, Assistant Secretary and Chief Administrative and Legal Officer |
| Patty Spiller | Senior Vice President of Marketing |
| Christina Antoniou | Senior Vice President and Head of Corporate Development |
| Stacey Kraft | Chief People Officer |
| Dr. Nike Beaubier M.D. | Senior Vice President of Life Science Pathology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 5, 2024 | 8-K | Current Report |
| Nov 5, 2024 | SCHEDULE 13G | Filing |
| Nov 4, 2024 | 10-Q | Quarterly Report |
| Nov 4, 2024 | 8-K | Current Report |
| Sep 6, 2024 | 8-K | Current Report |
| Aug 20, 2024 | 8-K | Current Report |
| Aug 20, 2024 | 4 | Statement of changes in beneficial ownership of securities |
| Aug 8, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |